Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 433

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

ADMA and oxidative stress

Sydow, Karsten, Münzel, Thomas·2003·Atherosclerosis Supplements
DOI 10.1016/s1567-5688(03)00033-3
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1567-5688(03)00033-3

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 109

  1. Suwaidi, 2000, Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction, Circulation, 101, 948, 10.1161/01.CIR.101.9.948 · DOI · Paper page
  2. Heitzer, 2001, Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease, Circulation, 104, 2673, 10.1161/hc4601.099485 · DOI · Paper page
  3. Cooke, 2000, Does ADMA cause endothelial dysfunction?, Arterioscler Thromb Vasc Biol, 20, 2032, 10.1161/01.ATV.20.9.2032 · DOI · Paper page
  4. Surdacki, 1999, Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension, J Cardiovasc Pharmacol., 33, 652, 10.1097/00005344-199904000-00020 · DOI · Paper page
  5. Böger, 1998, Asymmetric dimethylarginine (ADMA) a novel risk factor for endothelial dysfunction its role in hypercholesterolemia, Circulation, 98, 1842, 10.1161/01.CIR.98.18.1842 · DOI · Paper page
  6. Sydow, 2003, ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins, Cardiovasc. Res., 57, 244, 10.1016/S0008-6363(02)00617-X · DOI · Paper page
  7. Böger, 1997, Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease, Circulation, 95, 2068, 10.1161/01.CIR.95.8.2068 · DOI · Paper page
  8. Yoo, 2001, Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke, Atherosclerosis, 158, 425, 10.1016/S0021-9150(01)00444-0 · DOI · Paper page
  9. Gorenflo, 2001, Plasma levels of asymmetrical dimethyl-l-arginine in patients with congenital heart disease and pulmonary hypertension, J Cardiovasc Pharmacol., 37, 489, 10.1097/00005344-200104000-00016 · DOI
  10. Kielstein, 1999, Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease, J. Am. Soc. Nephrol., 10, 594, 10.1681/ASN.V103594 · DOI · Paper page
  11. Zoccali, 2001, Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study, Lancet, 358, 2113, 10.1016/S0140-6736(01)07217-8 · DOI · Paper page
  12. Myers, 1990, Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide, Nature, 345, 161, 10.1038/345161a0 · DOI · Paper page
  13. Radomski, 1987, The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide, Br. J. Pharmacol., 92, 639, 10.1111/j.1476-5381.1987.tb11367.x · DOI · Paper page
  14. Garg, 1989, Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells, J. Clin. Invest., 83, 1774, 10.1172/JCI114081 · DOI · Paper page
  15. Gryglewski, 1986, Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor, Nature, 320, 454, 10.1038/320454a0 · DOI · Paper page
  16. Beckman, 1996, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly, Am. J. Physiol., 271, C1424, 10.1152/ajpcell.1996.271.5.C1424 · DOI · Paper page
  17. Suarna, 1995, Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate, Arterioscler Thromb Vasc Biol., 15, 1616, 10.1161/01.ATV.15.10.1616 · DOI · Paper page
  18. Diaz, 1997, Antioxidants and atherosclerotic heart disease, N Engl J Med., 337, 408, 10.1056/NEJM199708073370607 · DOI · Paper page
  19. Griendling, 2000, NAD(P)H oxidase: role in cardiovascular biology and disease, Circ. Res., 86, 494, 10.1161/01.RES.86.5.494 · DOI · Paper page
  20. Eiserich, 2002, Myeloperoxidase a leukocyte-derived vascular NO oxidase, Science, 296, 2391, 10.1126/science.1106830 · DOI · Paper page
  21. Vasquez-Vivar, 1998, Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors, Proc. Natl. Acad. Sci. U.S.A., 95, 9220, 10.1073/pnas.95.16.9220 · DOI · Paper page
  22. Xia, 1998, Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process, J. Biol. Chem., 273, 25804, 10.1074/jbc.273.40.25804 · DOI · Paper page
  23. Laursen, 2001, Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin, Circulation, 103, 1282, 10.1161/01.CIR.103.9.1282 · DOI · Paper page
  24. Milstien, 1999, Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function, Biochem Biophys Res Commun., 263, 681, 10.1006/bbrc.1999.1422 · DOI · Paper page
  25. Olken, 1993, NG-methyl-l-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase, Biochemistry, 32, 9677, 10.1021/bi00088a020 · DOI · Paper page
  26. Pou, 1999, Mechanism of superoxide generation by neuronal nitric-oxide synthase, J Biol Chem., 274, 9573, 10.1074/jbc.274.14.9573 · DOI · Paper page
  27. Pritchard, 1995, Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion, Circ. Res., 77, 510, 10.1161/01.RES.77.3.510 · DOI · Paper page
  28. Vergnani, 2000, Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of l-arginine availability, Circulation, 101, 1261, 10.1161/01.CIR.101.11.1261 · DOI · Paper page
  29. Böger, 2000, LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases, Circ. Res., 87, 99, 10.1161/01.RES.87.2.99 · DOI · Paper page
  30. Vallance, 1992, Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure, Lancet, 339, 572, 10.1016/0140-6736(92)90865-Z · DOI · Paper page
  31. Achan, 2003, Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase, Arterioscler Thromb Vasc Biol., 23, 1455, 10.1161/01.ATV.0000081742.92006.59 · DOI · Paper page
  32. Lin, 2002, Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase, Circulation, 106, 987, 10.1161/01.CIR.0000027109.14149.67 · DOI · Paper page
  33. Stühlinger, 2001, Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine, Circulation, 104, 2569, 10.1161/hc4601.098514 · DOI · Paper page
  34. Starkebaum, 1986, Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine, J Clin Invest, 77, 1129, 10.1172/JCI112442 · DOI · Paper page
  35. Lang, 2000, Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions, Arterioscler. Thromb. Vasc. Biol., 20, 422, 10.1161/01.ATV.20.2.422 · DOI · Paper page
  36. Leiper, 2002, S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase, Proc Natl Acad Sci USA, 99, 13527, 10.1073/pnas.212269799 · DOI · Paper page
  37. Hink, 2002, Mechanisms underlying endothelial dysfunction in diabetes mellitus, Circ Res, 88, E14, 10.1161/01.RES.88.2.e14 · DOI · Paper page
  38. Guzik, 2002, Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase, Circulation, 105, 1656, 10.1161/01.CIR.0000012748.58444.08 · DOI · Paper page
  39. Drexler, 1991, Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine, Lancet, 338, 1546, 10.1016/0140-6736(91)92372-9 · DOI · Paper page
  40. O’Driscoll, 1997, Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus, J Clin Invest., 100, 678, 10.1172/JCI119580 · DOI · Paper page
  41. O’Driscoll, 1999, Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus, J Am Coll Cardiol., 33, 1506, 10.1016/S0735-1097(99)00065-0 · DOI · Paper page
  42. Solzbach, 1997, Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients, Circulation, 96, 1513, 10.1161/01.CIR.96.5.1513 · DOI · Paper page
  43. Heitzer, 1996, Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL, Circulation, 93, 1346, 10.1161/01.CIR.93.7.1346 · DOI · Paper page
  44. Tawakol, 1997, Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans, Circulation, 95, 1119, 10.1161/01.CIR.95.5.1119 · DOI · Paper page
  45. Vita, 1990, Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease, Circulation, 81, 491, 10.1161/01.CIR.81.2.491 · DOI · Paper page
  46. Hornig, 1998, Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure, Circulation, 97, 363, 10.1161/01.CIR.97.4.363 · DOI · Paper page
  47. Böger, 1998, Restoring vascular nitric oxide formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease, J Am Coll Cardiol., 32, 1336, 10.1016/S0735-1097(98)00375-1 · DOI · Paper page
  48. Bolton, 2001, Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines, Nephrol Dial Transplant., 16, 1189, 10.1093/ndt/16.6.1189 · DOI · Paper page
  49. van Guldener, 1998, . Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients, Nephrol Dial Transplant., 13, 1782, 10.1093/ndt/13.7.1782 · DOI
  50. Warnholtz, 1999, Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin–angiotensin system, Circulation, 99, 2027, 10.1161/01.CIR.99.15.2027 · DOI · Paper page
  51. Mollnau, 2003, Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells, Arterioscler Thromb Vasc Biol., 23, 615, 10.1161/01.ATV.0000065234.70518.26 · DOI
  52. Griendling, 1994, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells, Circ Res, 74, 1141, 10.1161/01.RES.74.6.1141 · DOI · Paper page
  53. Rajagopalan, 1996, Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation Contribution to alterations of vasomotor tone, J Clin Invest., 97, 1916, 10.1172/JCI118623 · DOI · Paper page
  54. Cosentino, 1998, Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats, J Clin Invest., 101, 1530, 10.1172/JCI650 · DOI · Paper page
  55. Heitzer, 2000, Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase, Circ Res., 97, 1129
  56. Walker, 2001, Endothelium-dependent vasodilation is independent of the plasma l-arginine/ADMA ratio in men with stable angina: lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance, J Am Coll Cardiol., 38, 499, 10.1016/S0735-1097(01)01380-8 · DOI
  57. Hornig, 2001, Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase, Circulation, 103, 799, 10.1161/01.CIR.103.6.799 · DOI · Paper page
  58. Landmesser, 2002, Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase, Circulation, 106, 3073, 10.1161/01.CIR.0000041431.57222.AF · DOI · Paper page
  59. Belch, 1995, Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus, Int Angiol, 14, 385
  60. Annuk, 2001, Oxidative stress and endothelial function in chronic renal failure, J Am Soc Nephrol, 12, 2747, 10.1681/ASN.V12122747 · DOI · Paper page
  61. Schneider, 2003, l-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats, Kidney Int., 64, 216, 10.1046/j.1523-1755.2003.00063.x · DOI
  62. Münzel, 1995, Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance, J Clin Invest, 95, 187, 10.1172/JCI117637 · DOI · Paper page
  63. Gori, 2001, Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study, Circulation, 104, 1119, 10.1161/hc3501.095358 · DOI · Paper page
  64. Gori, 2001, Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans, J Am Coll Cardiol, 38, 1096, 10.1016/S0735-1097(01)01510-8 · DOI
  65. Warnholtz, 2002, Adverse effects of nitroglycerin treatment on endothelial function vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits, J Am Coll Cardiol, 40, 1356, 10.1016/S0735-1097(02)02133-2 · DOI
  66. Münzel, 2000, Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability, Circ Res., 86, E7, 10.1161/01.RES.86.1.e7 · DOI · Paper page
  67. Clarkson, 1997, Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults, J Clin Invest., 97, 1989, 10.1172/JCI118632 · DOI · Paper page
  68. Abou-Mohamed, 1996, Role of l-arginine in the vascular actions and development of tolerance to nitroglycerin, Br J Pharmacol., 130, 211, 10.1038/sj.bjp.0703293 · DOI
  69. Stroes, 1997, Tetrahydrobiopterin restores endothelial function in hypercholesterolemia, J Clin Invest., 99, 41, 10.1172/JCI119131 · DOI · Paper page
  70. Title, 2000, Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease, J Am Coll Cardiol., 36, 758, 10.1016/S0735-1097(00)00809-3 · DOI · Paper page
  71. Doshi, 2001, Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide, Arterioscler Thromb Vasc Biol., 21, 1196, 10.1161/hq0701.092000 · DOI · Paper page
  72. Parker, 2002, The effect of supplemental l-arginine on tolerance development during continuous transdermal nitroglycerin therapy, J Am Coll Cardiol., 39, 1199, 10.1016/S0735-1097(02)01729-1 · DOI
  73. Förstermann, 1991, Isoforms of nitric oxide synthase. Characterization and purification from different cell types, Biochem Pharmacol., 42, 1849, 10.1016/0006-2952(91)90581-O · DOI · Paper page
  74. Bode-Böger, 1996, Elevated l-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits, Biochem Biophys Res Commun., 219, 598, 10.1006/bbrc.1996.0279 · DOI · Paper page
  75. Rector, 1996, Randomized, double-blind placebo-controlled study of supplemental oral l-arginine in patients with heart failure, Circulation, 93, 2135, 10.1161/01.CIR.93.12.2135 · DOI · Paper page
  76. Hand, 1996, Hemodialysis and l-arginine, but not d-arginine, correct renal failure-associated endothelial dysfunction, Kidney Int., 53, 1068, 10.1111/j.1523-1755.1998.00851.x · DOI
  77. Egashira, 1996, Effects of l-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms, Circulation, 94, 130, 10.1161/01.CIR.94.2.130 · DOI
  78. Morris, 2002, Regulation of enzymes of the urea cycle and arginine metabolism, Annu Rev Nutr., 22, 87, 10.1146/annurev.nutr.22.110801.140547 · DOI · Paper page
  79. Grody, 1987, Human arginase isozymes, Isozymes Curr Top Biol Med Res., 13, 181
  80. Griffith, 1995, Nitric oxide synthases: properties and catalytic mechanism, Annu Rev Physiol., 57, 707, 10.1146/annurev.ph.57.030195.003423 · DOI · Paper page
  81. Lass, 2002, Functional and analytical evidence for scavenging of oxygen radicals by l-arginine, Mol Pharmacol., 61, 1081, 10.1124/mol.61.5.1081 · DOI
  82. Laursen, 2001, Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin, Circulation, 103, 1282, 10.1161/01.CIR.103.9.1282 · DOI · Paper page
  83. Feng, 1998, Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure, Cardiovasc. Res., 37, 667, 10.1016/S0008-6363(97)00242-3 · DOI
  84. Piatti, 2003, Acute intravenous l-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels, Circulation, 107, 429, 10.1161/01.CIR.0000046489.24563.79 · DOI
  85. Ito, 2001, Renin–angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension, Jpn Circ J., 65, 775, 10.1253/jcj.65.775 · DOI
  86. Chen, 2002, Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X, Am J Cardiol, 90, 974, 10.1016/S0002-9149(02)02664-4 · DOI · Paper page
  87. Ito, 2002, Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J, 266, 811
  88. Delles, 2002, Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension, Am J Hypertens., 15, 590, 10.1016/S0895-7061(02)02278-1 · DOI
  89. Böger, 1997, Dietary l-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin, Circulation, 96, 1282, 10.1161/01.CIR.96.4.1282 · DOI · Paper page
  90. Eid, 2003, Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin, Atherosclerosis, 166, 279, 10.1016/S0021-9150(02)00206-X · DOI
  91. Pereira, 2003, Effects of simvastatin and l-arginine on vasodilation, Free Radic Res., 37, 529, 10.1080/1071576031000083170 · DOI
  92. Paiva, 2003, Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors, J Cardiovasc Pharmacol., 41, 219, 10.1097/00005344-200302000-00010 · DOI
  93. Stühlinger, 2002, Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor, JAMA, 287, 1420, 10.1001/jama.287.11.1420 · DOI · Paper page
  94. Asagami, 2002, Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes, Metabolism, 51, 843, 10.1053/meta.2002.33349 · DOI · Paper page
  95. Jiang, 2002, Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level, Br J Pharmacol., 135, 1175, 10.1038/sj.bjp.0704563 · DOI
  96. Jiang, 2003, Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine, Naunyn Schmiedebergs Arch Pharmacol., 367, 600, 10.1007/s00210-003-0756-x · DOI
  97. Teerlink, 2003, Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women, Clin Sci (Lond), 105, 67, 10.1042/CS20020309 · DOI
  98. Holven, 2003, Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects, Br J Nutr., 89, 359, 10.1079/BJN2002779 · doi:10.1079/bjn2002779
  99. Böger, 2000, Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia, Arterioscler Thromb Vasc Biol., 20, 1557, 10.1161/01.ATV.20.6.1557 · DOI · Paper page
  100. Chin-Dusting, 1996, Dietary supplementation with l-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure, J Am Coll Cardiol., 27, 1207, 10.1016/0735-1097(95)00611-7 · DOI
  101. Cross, 2001, Acute administration of l-arginine does not improve arterial endothelial function in chronic renal failure, Kidney Int., 60, 2318, 10.1046/j.1523-1755.2001.00059.x · DOI
  102. Miller, 2003, Effects of an acute dose of l-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial, Am J Nephrol., 23, 91, 10.1159/000068036 · doi:10.1159/000068036
  103. Cheetham, 2000, Stanton, K, Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes, J Am Coll Cardiol., 36, 1461, 10.1016/S0735-1097(00)00933-5 · DOI
  104. Cheetham, 2001, Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes, Clin Sci (Lond)., 100, 13, 10.1042/CS20000122 · doi:10.1042/cs20000122
  105. Münzel, 2001, Are ACE inhibitors a “magic bullet” against oxidative stress?, Circulation, 104, 1571, 10.1161/hc3801.095585 · DOI · Paper page
  106. Tsunekawa, 2001, Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days, Circulation, 104, 376, 10.1161/hc2901.094094 · DOI · Paper page
  107. Mullen, 2000, Atorvastatin but not l-arginine improves endothelial function in type I diabetes mellitus: a double-blind study, J Am Coll Cardiol., 36, 410, 10.1016/S0735-1097(00)00743-9 · DOI
  108. Wagner, 2000, Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation, Arterioscler Thromb Vasc Biol., 20, 61, 10.1161/01.ATV.20.1.61 · DOI · Paper page
  109. Laufs, 1998, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation, 97, 1129, 10.1161/01.CIR.97.12.1129 · DOI · Paper page

Cited by

See all 433

Metadata

Authors
Sydow, K., & Münzel, T.
Venue
Atherosclerosis Supplements
Publisher
Elsevier BV
Published
2003-12
Volume
4
Issue
4
Pages
41-51
ISSN
1567-5688 (ISSN-L)
DOI
10.1016/s1567-5688(03)00033-3
OpenAlex
W1973223262
Cited by
433
References
8
FWCI
10.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADMA and oxidative stress. https://app.cochat.ai/papers/10.1016/s1567-5688(03)00033-3
The paper
Sydow, K., & Münzel, T. (2003). ADMA and oxidative stress. Atherosclerosis Supplements. https://doi.org/10.1016/s1567-5688(03)00033-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.